Combined effect of C-reactive protein and stavudine on adipogenesis

Stankov M.V. , Behrens G.M. HIV-therapy associated lipodystrophy: experimental and clinical evidence for the pathogenesis and treatment. Endocr Metab Immune Disord Drug Targets 2007; 7: 237–249.

Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006; 444: 860–867.

Dandona P. , Aljada A. , Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4–7.

Shoelson S.E. , Lee J. , Goldfine A.B. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793–1801.

Wellen K.E. , Hotamisligil G.S. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111–1119.

Moshage H.J. , Roelofs H.M. , van Pelt J.F. The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. Biochem Biophys Res Commun 1988; 155: 112–117.

Calabro P. , Chang D.W. , Willerson J.T. , Yeh E.T. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol 2005; 46: 1112–1113.

Samaras K. , Wand H. , Law M. , Emery S. , Cooper D. , Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007; 30: 113–119.

Festa A. , D'Agostino R. Jr. , Tracy R.P. , Haffner S.M. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002; 51: 1131–1137.

Freeman D.J. , Norrie J. , Caslake M.J. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002; 51: 1596–1600.

Frohlich M. , Imhof A. , Berg G. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000; 23: 1835–1839.

Aronson D. , Bartha P. , Zinder O. Association between fasting glucose and C-reactive protein in middle-aged subjects. Diabet Med 2004; 21: 39–44.

Ouchi N. , Kihara S. , Funahashi T. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003; 107: 671–674.

Schulze M.B. , Rimm E.B. , Shai I. , Rifai N. , Hu F.B. Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care 2004; 27: 1680–1687.

Yuan G. , Chen X. , Ma Q. C-reactive protein inhibits adiponectin gene expression and secretion in 3T3-L1 adipocytes. J Endocrinol 2007; 194: 275–281.

Gougeon M.L. , Penicaud L. , Fromenty B. , Leclercq P. , Viard J.P. , Capeau J. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antivir Ther 2004; 9: 161–177.

Lagathu C. , Bastard J.P. , Auclair M. , Maachi M. , Capeau J. , Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 2003; 311: 372–379.

Caron M. , Auclair M. , Vigouroux C. , Glorian M. , Forest C. , Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001; 50: 1378–1388.

Maeda N. , Takahashi M. , Funahashi T. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094–2099.

Nolan D. , Mallal S. The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome. J HIV Ther 2004; 9: 34–40.

Nolan D. , Hammond E. , Martin A. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17: 1329–1338.

Nolan D. , Hammond E. , James I. , McKinnon E. , Mallal S. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther 2003; 8: 617–626.

Stankov M.V. , Schmidt R.E. , Behrens G.M. Zidovudine impairs adipogenic differentiation through inhibition of clonal expansion. Antimicrob Agents Chemother 2008; 52: 2882–2889.

Rozen S. , Skaletsky H.J. Primer3 on the www for general users and for biologist programmers. In Krawetz S. , Misener S. (Editors). Bioinformatics methods and protocols: methods in molecular biology. Totowa: Humana Press 2000; pp. 365–386.

Gorzelniak K. , Janke J. , Engeli S. , Sharma A.M. Validation of endogenous controls for gene expression studies in human adipocytes and preadipocytes. Horm Metab Res 2001; 33: 625–627.

Spiegelman B.M. , Farmer S.R. Decreases in tubulin and actin gene expression prior to morphological differentiation of 3T3 adipocytes. Cell 1982; 29: 53–60.

An Z. , Wang H. , Song P. , Zhang M. , Geng X. , Zou M.H. Nicotine-induced activation of AMP-activated protein kinase inhibits fatty acid synthase in 3T3L1 adipocytes: a role for oxidant stress. J Biol Chem 2007; 282: 26793–26801.

Riccardi C. , Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 2006; 1: 1458–1461.

Caron M. , Auclair M. , Lagathu C. The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. AIDS 2004; 18: 2127–2136.

Stankov M.V. , Lucke T. , Das A.M. , Schmidt R.E. , Behrens G.M. Relationship of mitochondrial DNA depletion and respiratory chain activity in preadipocytes treated with nucleoside reverse transcriptase inhibitors. Antivir Ther 2007; 12: 205–216.

Masia M. , Bernal E. , Padilla S. The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients. Atherosclerosis 2007; 195: 167–171.

Viengchareun S. , Caron M. , Auclair M. Mitochondrial toxicity of indinavir, stavudine and zidovudine involves multiple cellular targets in white and brown adipocytes. Antivir Ther 2007; 12: 919–929.

Lagathu C. , Eustace B. , Prot M. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther 2007; 12: 489–500.

Lagathu C. , Bastard J.P. , Auclair M. Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro.Antivir Ther 2004; 9: 911–920.

Spalding K.L. , Arner E. , Westermark P.O. Dynamics of fat cell turnover in humans. Nature 2008; 453: 783–787.

Bastard J.P. , Caron M. , Vidal H. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359: 1026–1031.

Fasshauer M. , Kralisch S. , Klier M. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2003; 301: 1045–1050.

Lagathu C. , Yvan-Charvet L. , Bastard J.P. Long-term treatment with interleukin-1p induces insulin resistance in murine and human adipocytes. Diabetologia 2006; 49: 2162–2173.

Ruan H. , Hacohen N. , Golub T.R. , Van Parijs L. , Lodish H.F. Tumor necrosis factor-α suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-κB activation by TNF-α is obligatory. Diabetes 2002; 51: 1319–1336.

Zhang H.H. , Kumar S. , Barnett A.H. , Eggo M.C. Dexamethasone inhibits tumor necrosis factor-α-induced apoptosis and interleukin-1 P release in human subcutaneous adipocytes and preadipocytes. J Clin Endocrinol Metab 2001; 86: 2817–2825.

Lefterova M.I. , Zhang Y. , Steger D.J. PPARγ and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. Genes Dev 2008; 22: 2941–2952.

Dudley M.N. , Graham K.K. , Kaul S. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J Infect Dis 1992; 166: 480–485.

Maeda K. , Okubo K. , Shimomura I. , Funahashi T. , Matsuzawa Y. , Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286–289.

Chaldakov G.N. , Stankulov I.S. , Hristova M. , Ghenev P.I. Adipobiology of disease: adipokines and adipokine-targeted pharmacology. Curr Pharm Des 2003; 9: 1023–1031.

Berg A.H. , Combs T.P. , Scherer P.E. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002; 13: 84–89.

Combs T.P. , Wagner J.A. , Berger J. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: a potential mechanism of insulin sensitization. Endocrinology 2002; 143: 998–1007.

Hernandez R. , Teruel T. , de Alvaro C. , Lorenzo M. Rosiglitazone ameliorates insulin resistance in brown adipocytes of Wistar rats by impairing TNF-α induction of p38 and p42/p44 mitogen-activated protein kinases. Diabetologia 2004; 47: 1615–1624.

Iwaki M. , Matsuda M. , Maeda N. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003; 52: 1655–1663.